中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

8 records (took 0.013 seconds)

    PHARMACEUTICAL COMBINATIONS
    2.
    发明申请
    PHARMACEUTICAL COMBINATIONS 有权

    公开(公告)号：US20210386763A1

    公开(公告)日：2021-12-16

    申请号：US17415985

    申请日：2019-12-18

    Applicant: NOVARTIS AG

    Inventor： Nelson GUERREIRO ,  Ensar HALILOVIC ,  Astrid JULLION ,  Christophe MEILLE ,  Youzhen WANG

    IPC: A61K31/635 ,  A61K31/506 ,  A61K45/06 ,  A61P35/02

    Abstract: The present invention relates to the combination of the HDM2-p53 interaction inhibitor drug (S)-5-(5-Chloro-1-methyl-2-oxo-1,2-dihydro-pyridin-3-yl)-6-(4-chloro-phenyl)-2-(2,4-dimethoxy-pyrimidin-5-yl)-1-isopropyl-5,6-dihydro-1H-pyrrolo[3,4-d]imidazol-4-one [HDM201] and the BCL2 inhibitor 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-[(3-nitro-4-{[(oxan-4yl)methyl]amino}phenyl)sulfonyl]-2-[(1H-pyrrolo[2,3-b]pyridin-5-yl)oxy]benzamide [venetoclax]. The present invention further relates to the use of said combination in the treatment of cancer, in particular hematological tumors. The present invention further relates to dose and dosing regimen related to this combination cancer treatment.

    PHARMACEUTICAL COMBINATIONS
    4.
    发明申请
    PHARMACEUTICAL COMBINATIONS 审中-公开

    公开(公告)号：US20190134033A1

    公开(公告)日：2019-05-09

    申请号：US16180078

    申请日：2018-11-05

    Applicant: Novartis AG

    Inventor： Fang LI ,  Hui-Qin WANG ,  Ensar HALILOVIC ,  Jinsheng LIANG

    IPC: A61K31/506 ,  A61K31/496 ,  A61K31/435 ,  A61K45/06 ,  A61K31/4025 ,  A61K31/404

    Abstract: A pharmaceutical combination comprising (a) an ALK inhibitor, or a pharmaceutically acceptable salt thereof, and (b) at least one HDMA-2/p53 receptor inhibitor or a pharmaceutically acceptable salt, or at least one BRaf inhibitor or a pharmaceutically acceptable salt, and optionally a pharmaceutically acceptable carrier, for simultaneous, separate or sequential administration; the uses of such combination in the treatment of cancer; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination.

    PHARMACEUTICAL COMBINATIONS
    6.
    发明申请
    PHARMACEUTICAL COMBINATIONS 有权

    公开(公告)号：US20210363254A1

    公开(公告)日：2021-11-25

    申请号：US16981828

    申请日：2019-03-18

    Applicant: Novartis AG

    Inventor： Stephane FERRETTI ,  Nelson GUERREIRO ,  Ensar HALILOVIC ,  Sebastien JEAY ,  Astrid JULLION ,  Jinsheng LIANG ,  Christophe MEILLE ,  Hui-Qin WANG ,  Jens WUERTHNER

    IPC: C07K16/28 ,  A61P35/00 ,  C07D487/04

    Abstract: The present invention relates to a pharmaceutical combination which comprises (a) at least one antibody molecule (e.g., humanized antibody molecules) that bind to Programmed Death 1 (PD-1), and (b) a HDM2-p53 interaction inhibitor, said combination for simultaneous, separate or sequential administration for use in the treatment of a proliferative disease, a pharmaceutical composition comprising such combination; a method of treating a subject having a proliferative disease comprising administration of said combination to a subject in need thereof; use of such combination for the treatment of proliferative disease; and a commercial package comprising such combination; said proliferative disease being a TP53 wildtype tumor, in particular TP53 wildtype renal cell carcinoma (RCC) or TP53 wildtype colorectal cancer (CRC).

Patent Agency Ranking